Currently, a global, double-blind, phase 3 study with PFS and OS as co-primary endpoints (E2112, N = 600, NCT02115282) and a Chinese phase 3 study with PFS as primary endpoint (N = 327, NCT03538171) are being conducted in patients with HR+/HER2− advanced or metastatic BC. This evidence concerns the gene HR and breast cancer.